News
Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD - - Broadens global development program for vereki ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback